Baseline Productions

Baseline Productions Debt/Market Cap

The Debt to Market Capitalization Ratio of Baseline Productions (BSSP) as of Nov 15, 2026 is 141,655.93 %. In the previous year, Debt to Market Capitalization Ratio was 141,333.25 % — a change of 0.23% (higher).

Debt/Market Cap

141,655.93 %

YoY

0.23%

Last updated:

Debt to Market Capitalization Ratio of Baseline Productions is 2020 141,655.93 % . Debt to Market Capitalization Ratio of Baseline Productions was 2019 141,333.25 % . It decreases by 0.23% higher compared to the previous year.

The Baseline Productions Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2014
67,273.66 USD
Jan 1, 2019
141,333.25 USD
Jan 1, 2020
141,655.93 USD
The Baseline Productions Debt/Market Cap history
YEARDebt/Market CapYoY
141,655.93 %+0.23%
141,333.25 %+110.09%
67,273.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

Debt to Market Capitalization Ratio of Baseline Productions is 141,655.93 % in 2020.

Debt to Market Capitalization Ratio of Baseline Productions changed from 141,333.25 % to 141,655.93 %, representing a 0.23% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's Baseline Productions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Baseline Productions

All Key Metrics — Baseline Productions